COVID-19
Conditions
Brief summary
In this study invetigators propose to administer clazakizumab to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a double-blinded randomized multi-center trial designed as a phase II dose-finding three arm trial with seamless adaptive transition to a phase III efficacy trial. For phase II, patients were randomized 1:1:1 ratio to three study arms and received clazakizumab at a dose of 12.5 mg, 25 mg or placebo. Based on interim analysis, the low dose arm was dropped and the phase III portion of the study continued to enroll patients randomized 1:1 to high dose clazakizumab or placebo. Based on interim analysis, the remaining 10 subjects at NYU will be randomly assigned to a 1:1 ratio to two arms that will receive clazakizumab at a dose of 25 mg or placebo. The NYU site will serve as the central data management site for other centers who undertake this protocol. Other sites will enroll patients based on the two arm 1:1 randomization. 60 patients at outside sites are expected to enroll.
Detailed description
The limited understanding of the clinical behavior of patients infected with SARS-CoV-2 (the viral organism responsible for COVID-19 disease) is evolving on a daily basis. Reports from China indicate that a subset of patients with the worst clinical outcomes may manifest cytokine storm syndrome. Hypotheses that excess cytokines may trigger a secondary hemophagocytic lymphhistiocytosis (sHLH) have been proposed. Indeed, cytokine profiles consistent with this picture were observed in Chinese patients with severe pulmonary involvement. Specifically, elevated ferritin and interleukin-6 (IL-6) were associated with fatalities among the infected patients. A role for targeted anti-inflammatory and anti-cytokine therapies in the treatment of pulmonary hyperinflammation has been proposed. Clazakizumab is a genetically engineered humanized IgG1 monoclonal antibody (mAb) that binds with high affinity to human IL-6. This investigational agent is currently being studied as a treatment for chronic active antibody mediated rejection of renal allografts. In this study investigators propose to administer clazakizumab to patients with life-threatening pulmonary failure secondary to COVID-19 disease.
Interventions
DRUGClazakizumab 25 mg
The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
DRUGClazakizumab 12.5 mg
The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
OTHERPlacebo
The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
Sponsors
NYU Langone Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
This study is double-blind and therefore neither the Investigator, the subject, the Sponsor and its representatives, nor other designated study site personnel involved in running of the study will be aware of the identification of the investigational drug administered to each subject.
Intervention model description
This is a randomized, double-blind, placebo-controlled, adaptive seamless Phase II/III design (ASD). We propose the administration of an investigational drug in patients with high predicted short-term mortality secondary to COVID-19 disease. 80 patients were randomly assigned in a 1:1:1 ratio to three study arms that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo. Interim analyses occurred every 7 days since the enrollment of the first 30 patients. Based on week 4 interim analysis the DSMB has recommendation discontinuing the low-dose 12.5 mg of clazakizumab arm. The DSMB has advised continuing enrollment in the placebo and high-dose 25mg of clazakizumab arms in a 1:1 randomization.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to be eligible to participate in this study, the patients must meet all of the following criteria: 1. At least 18 years of age 2. Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time RT-PCR using nasopharyngeal swab sample, or equivalent test available to be performed by the NYU Langone clinical laboratory). Effort will be made to have the confirmatory test result \<72 hours prior to enrollment however given overall clinical demand this may not be feasible in all cases. 3. Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of \<200), OR SpO2 \< 90% on 4L (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, PLUS 2 or more of the following predictors for severe disease: CRP \> 35 mg/L Ferritin \> 500 ng/mL D-dimer \> 1000 mg/mL Neutrophil-Lymphocyte Ratio \> 4 LDH \> 200 U/L Increase in troponin in patient w/out known cardiac disease 4. Has a consent designee willing to provide informed consent on behalf of the patient (this assumes that a mechanically ventilated patients lacks capacity to consent on his/her own behalf. Should it be deemed that the patient has capacity to consent, consent may be obtained from the patient.) 5. Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as: 1. combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal) 2. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) 3. intrauterine device (IUD) 4. intrauterine hormone-releasing system (IUS) 5. vasectomized partner 6. bilateral tubal occlusion 7. true abstinence. when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence, such as calendar, ovulation, symptothermal, postovulation methods, and withdrawal are not acceptable methods of contraception. 6. Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent.
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: 1. Evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury) 2. Known active inflammatory bowel disease 3. Known active, untreated diverticulitis 4. Known untreated bacteremia 5. Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis). 6. Known hypersensitivity to the clazakizumab
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ventilator Free Survival | 28 days | Ventilator Free Survival is defined as the total number of patients who were alive and ventilator free at 28 days. |
| Number of Serious Adverse Events Associated With High and Low Dose of Clazakizumab | 60 days | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Patient Survival | 28 days | Overall Patient Survival is defined as the total number of patients per group who were alive at 28 days |
| Number of Participants With Change in Clinical Status | 28 days | Change in clinical status defined by an improvement in status by at least 2 score points on WHO 11-point ordinal scale, where 0 = uninfected; no viral RNA detected, 1 = asymptomatic; viral RNA detected, 2 = symptomatic; independent, 3 = symptomatic; assistance needed, 4 = hospitalized; no oxygen therapy, 5 = hospitalized; oxygen by mask or nasal prongs, 6 = hospitalized; oxygen by NIV or high flow, 7 = intubation and mechanical ventilation, pO2/FiO2 \>/= 150 or SpO2/FiO2 \>/= 200, 8 = mechanical ventilation pO2/FiO2 \< 150 (SpO2/FiO2 \< 200) or vasopressors, 9 = mechanical ventilation pO2/FiO2 \< 150 and vasopressors, dialysis, or ECMO, and 10 = Dead |
| Number of Participants With a Change in Clinical Status | 60 days | Change in clinical status defined by an improvement in status by at least 2 score points on WHO 11-point ordinal scale, where 0 = uninfected; no viral RNA detected, 1 = asymptomatic; viral RNA detected, 2 = symptomatic; independent, 3 = symptomatic; assistance needed, 4 = hospitalized; no oxygen therapy, 5 = hospitalized; oxygen by mask or nasal prongs, 6 = hospitalized; oxygen by NIV or high flow, 7 = intubation and mechanical ventilation, pO2/FiO2 \>/= 150 or SpO2/FiO2 \>/= 200, 8 = mechanical ventilation pO2/FiO2 \< 150 (SpO2/FiO2 \< 200) or vasopressors, 9 = mechanical ventilation pO2/FiO2 \< 150 and vasopressors, dialysis, or ECMO, and 10 = Dead |
| Number of Clazakizumab-expected Adverse Events | 60 days | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Clazakizumab 25 mg Clazakizumab 25 mg: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3. | 78 |
| Clazakizumab 12.5 mg Clazakizumab 12.5 mg: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3. | 26 |
| Placebo Placebo: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3. | 74 |
| Total | 178 |
Baseline characteristics
| Characteristic | Clazakizumab 25 mg | Total | Placebo | Clazakizumab 12.5 mg |
|---|---|---|---|---|
| Age, Continuous | 63.7 years STANDARD_DEVIATION 11.1 | 62.3 years STANDARD_DEVIATION 11.8 | 59.8 years STANDARD_DEVIATION 13.1 | 65.7 years STANDARD_DEVIATION 8.3 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 17 Participants | 49 Participants | 24 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 61 Participants | 129 Participants | 50 Participants | 18 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 7 Participants | 18 Participants | 9 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 16 Participants | 32 Participants | 12 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 30 Participants | 62 Participants | 26 Participants | 6 Participants |
| Race (NIH/OMB) White | 25 Participants | 66 Participants | 27 Participants | 14 Participants |
| Region of Enrollment United States | 78 participants | 178 participants | 74 participants | 26 participants |
| Sex: Female, Male Female | 25 Participants | 55 Participants | 20 Participants | 10 Participants |
| Sex: Female, Male Male | 53 Participants | 123 Participants | 54 Participants | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 22 / 78 | 6 / 26 | 28 / 74 |
| other Total, other adverse events | 76 / 78 | 24 / 26 | 72 / 74 |
| serious Total, serious adverse events | 24 / 78 | 6 / 26 | 33 / 74 |
Outcome results
Primary
Number of Serious Adverse Events Associated With High and Low Dose of Clazakizumab
Time frame: 60 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Clazakizumab 25 mg | Number of Serious Adverse Events Associated With High and Low Dose of Clazakizumab | 46 Serious Adverse Events |
| Clazakizumab 12.5 mg | Number of Serious Adverse Events Associated With High and Low Dose of Clazakizumab | 6 Serious Adverse Events |
| Placebo | Number of Serious Adverse Events Associated With High and Low Dose of Clazakizumab | 51 Serious Adverse Events |
Primary
Ventilator Free Survival
Ventilator Free Survival is defined as the total number of patients who were alive and ventilator free at 28 days.
Time frame: 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Clazakizumab 25 mg | Ventilator Free Survival | 58 Participants |
| Clazakizumab 12.5 mg | Ventilator Free Survival | 19 Participants |
| Placebo | Ventilator Free Survival | 44 Participants |
Secondary
Number of Clazakizumab-expected Adverse Events
Time frame: 60 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Clazakizumab 25 mg | Number of Clazakizumab-expected Adverse Events | 7 Adverse Events |
| Clazakizumab 12.5 mg | Number of Clazakizumab-expected Adverse Events | 3 Adverse Events |
| Placebo | Number of Clazakizumab-expected Adverse Events | 12 Adverse Events |
Secondary
Number of Participants With a Change in Clinical Status
Change in clinical status defined by an improvement in status by at least 2 score points on WHO 11-point ordinal scale, where 0 = uninfected; no viral RNA detected, 1 = asymptomatic; viral RNA detected, 2 = symptomatic; independent, 3 = symptomatic; assistance needed, 4 = hospitalized; no oxygen therapy, 5 = hospitalized; oxygen by mask or nasal prongs, 6 = hospitalized; oxygen by NIV or high flow, 7 = intubation and mechanical ventilation, pO2/FiO2 \>/= 150 or SpO2/FiO2 \>/= 200, 8 = mechanical ventilation pO2/FiO2 \< 150 (SpO2/FiO2 \< 200) or vasopressors, 9 = mechanical ventilation pO2/FiO2 \< 150 and vasopressors, dialysis, or ECMO, and 10 = Dead
Time frame: 60 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Clazakizumab 25 mg | Number of Participants With a Change in Clinical Status | 54 Participants |
| Clazakizumab 12.5 mg | Number of Participants With a Change in Clinical Status | 17 Participants |
| Placebo | Number of Participants With a Change in Clinical Status | 40 Participants |
Secondary
Number of Participants With Change in Clinical Status
Change in clinical status defined by an improvement in status by at least 2 score points on WHO 11-point ordinal scale, where 0 = uninfected; no viral RNA detected, 1 = asymptomatic; viral RNA detected, 2 = symptomatic; independent, 3 = symptomatic; assistance needed, 4 = hospitalized; no oxygen therapy, 5 = hospitalized; oxygen by mask or nasal prongs, 6 = hospitalized; oxygen by NIV or high flow, 7 = intubation and mechanical ventilation, pO2/FiO2 \>/= 150 or SpO2/FiO2 \>/= 200, 8 = mechanical ventilation pO2/FiO2 \< 150 (SpO2/FiO2 \< 200) or vasopressors, 9 = mechanical ventilation pO2/FiO2 \< 150 and vasopressors, dialysis, or ECMO, and 10 = Dead
Time frame: 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Clazakizumab 25 mg | Number of Participants With Change in Clinical Status | 50 Participants |
| Clazakizumab 12.5 mg | Number of Participants With Change in Clinical Status | 15 Participants |
| Placebo | Number of Participants With Change in Clinical Status | 37 Participants |
Secondary
Overall Patient Survival
Overall patient survival is defined as total number of patients per group who were alive at 60 days.
Time frame: 60 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Clazakizumab 25 mg | Overall Patient Survival | 56 Participants |
| Clazakizumab 12.5 mg | Overall Patient Survival | 20 Participants |
| Placebo | Overall Patient Survival | 46 Participants |
Secondary
Overall Patient Survival
Overall Patient Survival is defined as the total number of patients per group who were alive at 28 days
Time frame: 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Clazakizumab 25 mg | Overall Patient Survival | 60 Participants |
| Clazakizumab 12.5 mg | Overall Patient Survival | 20 Participants |
| Placebo | Overall Patient Survival | 54 Participants |